



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information


Description:	Recombinant human IL-33 (Interleukin 33), encompassing amino acids 109-270. This construct contains an N-terminal His-tag (6xHis) followed by an Avi-Tag™. This protein is enzymatically biotinylated using Avi-Tag™ technology. The recombinant protein was affinity purified.
Background:	IL-33 is a cytokine of the IL-1 family that is released in response to external triggers such as trauma, allergen exposure, and infections. IL-33 exists in a reduced or oxidized state, which trigger different signaling pathways. When in its reduced state (IL-33 ^{red}) it binds to IL-1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL-1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL-1RL1 initiates a signaling pathway that involves NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokines and chemokines. The soluble form of IL-1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease), and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is tozorakimab (MEDI3506), currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
Species:	Human
Construct:	IL-33 (His-Avi-109-270)-(Biotin)
Concentration:	0.38 mg/ml
Expression System:	HEK293
Purity:	84%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol.
MW:	21 kDa
Endotoxin Level:	121 EU/mg
Genbank Accession:	NM_033439.4
Label:	This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	Assay was performed according to IL1RL1:IL33 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (#82856) with increasing amounts of biotinylated IL-33.
Applications:	Useful for binding assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



IL33 Binding Activity to IL1RL1



Biotin-Avidin Pulldown

